drugset / Trial / NCT02825797
3BNC117 and 10-1074 in HIV-infected Individuals
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-08-01
- Completion
- 2018-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAFUVITUG | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | LAFUVITUG | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 30 mg/kg | Intravenous |